永笙生技股份有限公司
永笙生技股份有限公司（StemCyte）為全球性細胞治療公司，經營公私立臍帶血銀行並具備多國 GMP 細胞處理廠。核心業務包括臍帶血存儲、造血幹細胞與間質幹細胞在臨床治療（如中風、脊髓損傷）之研發。公司成立於 1997 年，總部位於台灣台北。
該股 RSI(6) 為 37.9，處於中性區間，短線無明顯超買超賣訊號。股價跌破5日、20日、60日、120日均線。短中期均線呈空頭排列，趨勢偏空。KD 指標中性（K=44.5）；MACD 柱狀體為正值，維持多方動能。 （自動產生 · 非投資建議）
| 日期 | 外資 | 投信 | 自營商 | 合計 |
|---|---|---|---|---|
| 09-24 | -10 | 0 | -3 | -13 |
| 09-23 | -1 | 0 | +2 | +1 |
| 09-22 | +4 | 0 | -1 | +3 |
| 09-21 | -4 | 0 | +2 | -2 |
| 09-18 | +25 | 0 | +3 | +28 |
| 09-17 | +14 | 0 | +2 | +16 |
| 09-16 | +9 | 0 | 0 | +9 |
| 09-15 | -4 | 0 | 0 | -4 |
| 09-14 | +11 | 0 | 0 | +11 |
| 09-11 | -39 | 0 | 0 | -39 |
| 09-10 | 0 | 0 | -1 | -1 |
| 09-09 | +19 | 0 | 0 | +19 |
| 09-08 | +7 | 0 | 0 | +7 |
| 09-07 | +5 | 0 | +1 | +6 |
| 09-04 | 0 | 0 | 0 | 0 |
| 09-03 | -2 | 0 | 0 | -2 |
| 09-02 | -22 | 0 | 0 | -22 |
| 09-01 | +2 | 0 | +2 | +4 |
| 08-31 | -42 | 0 | -1 | -43 |
| 08-28 | -19 | 0 | +2 | -17 |
| 08-27 | +23 | 0 | -2 | +21 |
| 08-26 | +29 | 0 | +3 | +32 |
| 08-25 | -5 | 0 | +1 | -4 |
| 08-24 | -4 | 0 | 0 | -4 |
| 08-21 | -2 | 0 | 0 | -2 |
| 08-20 | +25 | 0 | -1 | +24 |
| 08-19 | -10 | 0 | 0 | -10 |
| 08-18 | -35 | 0 | 0 | -35 |
| 08-17 | -26 | 0 | +3 | -23 |
| 08-14 | +3 | 0 | 0 | +3 |
| 08-13 | -11 | 0 | -1 | -12 |
| 08-12 | -21 | 0 | 0 | -21 |
| 08-11 | -28 | 0 | 0 | -28 |
| 08-10 | -37 | 0 | +1 | -36 |
| 08-07 | -33 | 0 | -2 | -35 |
| 08-06 | -78 | 0 | +2 | -76 |
| 08-05 | -11 | 0 | -2 | -13 |
| 08-04 | -61 | 0 | -4 | -65 |
| 08-03 | -4 | 0 | -30 | -34 |
| 07-31 | -22 | 0 | +1 | -21 |
| 07-30 | +29 | 0 | -38 | -9 |
| 07-29 | +44 | 0 | +4 | +48 |
| 07-28 | -36 | 0 | +56 | +20 |
| 07-27 | +23 | 0 | +7 | +30 |
| 07-24 | +1 | 0 | -1 | 0 |
| 07-23 | -157 | 0 | 0 | -157 |
| 07-22 | +97 | 0 | -6 | +91 |
| 07-21 | -48 | 0 | 0 | -48 |
| 07-20 | +208 | 0 | -3 | +205 |
| 07-17 | +40 | 0 | +5 | +45 |
| 07-16 | +21 | 0 | +2 | +23 |
| 07-15 | +84 | 0 | -4 | +80 |
| 07-14 | +70 | 0 | +9 | +79 |
| 07-13 | -53 | 0 | +4 | -49 |
| 07-09 | +30 | 0 | -2 | +28 |
| 07-08 | -106 | 0 | -3 | -109 |
| 07-07 | +71 | 0 | +3 | +74 |
| 07-06 | +116 | 0 | -3 | +113 |
| 07-03 | +149 | 0 | 0 | +149 |
| 07-02 | -16 | 0 | +2 | -14 |
| 07-01 | -22 | 0 | 0 | -22 |
| 06-30 | +102 | 0 | 0 | +102 |
| 06-29 | 0 | 0 | -1 | -1 |
| 06-26 | -156 | 0 | -1 | -157 |
| 06-25 | +67 | 0 | +2 | +69 |
| 06-24 | +56 | 0 | -2 | +54 |
| 06-22 | -76 | 0 | 0 | -76 |
| 06-18 | +16 | 0 | 0 | +16 |
| 06-17 | -27 | 0 | 0 | -27 |
| 06-16 | +143 | 0 | -1 | +142 |
| 06-15 | -28 | 0 | 0 | -28 |
| 06-12 | -52 | 0 | 0 | -52 |
| 06-10 | -5 | 0 | 0 | -5 |
| 06-09 | -49 | 0 | -1 | -50 |
| 06-08 | -11 | 0 | -2 | -13 |
| 06-04 | +36 | 0 | 0 | +36 |
| 06-03 | -113 | 0 | +2 | -111 |
| 06-02 | -24 | 0 | 0 | -24 |
| 06-01 | +223 | 0 | +23 | +246 |
| 05-29 | -45 | 0 | 0 | -45 |
| 月份 | 營收 | MoM% | YoY% |
|---|---|---|---|
| 2026/08 | 3197 萬 | -1.4% | +9.0% |
| 2026/07 | 3242 萬 | -4.1% | +13.7% |
| 2026/06 | 3379 萬 | +12.0% | +4.9% |
| 2026/05 | 3017 萬 | -7.7% | +5.0% |
| 2026/04 | 3267 萬 | +17.6% | - |
| 2026/03 | 2778 萬 | -4.5% | - |
| 2026/02 | 2908 萬 | - | - |